RxDoctor Payments Data

Daniel Mora Rivera, MD

Family Medicine · Orlando, FLNPI 1275578726

Payments from drug & device makers

$3,770in general payments, 2019–2025

Across 194 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$838
  • Pfizer$394
  • Astellas Pharma US Inc$294
  • AstraZeneca$228
  • Boehringer Ingelheim$228
  • Abbott$196
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$3,58595%
  • Education$1855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,770 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,692
Medicare patients
112
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$56,103
TrulicityDulaglutide30$44,523
EliquisApixaban23$40,187
FarxigaDapagliflozin Propanediol26$30,830
Atorvastatin Calcium192$1,845
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,836
Omeprazole71$1,692
Levothyroxine Sodium130$1,459
Metformin Hcl ErMetformin Hcl176$1,274
Rosuvastatin Calcium151$1,267
SynthroidLevothyroxine Sodium16$1,226
Ventolin HfaAlbuterol Sulfate14$1,220
Amlodipine Besylate138$1,146
Estradiol (Twice Weekly)Estradiol15$1,142
Gabapentin50$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$228$56,10333 claims
Lilly USA, LLCTrulicity$185$44,52330 claims
PfizerEliquis$394$40,18723 claims
AstraZenecaFarxiga$228$30,83026 claims
AbbVieSynthroid$190$1,22616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →